Format

Send to

Choose Destination
Clin Transl Med. 2014 Nov 22;3(1):61. doi: 10.1186/s40169-014-0038-x. eCollection 2014 Dec.

Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.

Author information

1
First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo, 160-0023 Japan.
2
Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1, Komaba, Meguro-Ku, Tokyo, 153-8904 Japan.
3
Clinical Protein Science & Imaging, Biomedical Center, Dept. of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden.
4
Biosys Technology, Daihyaku Seimei Toritsudai Ekimae Bldg 5 F 13-18, Nakane 2, Meguro-ku, Tokyo, 152-0031 Japan.
5
ThermoFisher Scientific, 3-9 Moriya-cho, Kanagawa-ku Yokohama, 221-0022 Japan.
6
National Medical Center for Children and Mothers Research Institute, 2-10-1 Okura Setagaya-ku, Tokyo 157-8535 Japan.
7
Dept. of Biophysics and Biochemistry, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871 Japan.
8
Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, Lund, Sweden 221 84, Lund, Sweden.
9
Center of Excellence in Biological and Medical mass spectrometry (CEBMMS), 221 84 Lund, Sweden.
10
First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo, 160-0023 Japan ; Clinical Protein Science & Imaging, Biomedical Center, Dept. of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden ; Center of Excellence in Biological and Medical mass spectrometry (CEBMMS), 221 84 Lund, Sweden.

Abstract

The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers. Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.

KEYWORDS:

Biobanking; Cancer diseases; HUPO; MRM; Mass spectrometry; Protein quantification; Proteomics

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center